The Pharma Data

DECEMBER 31, 2020

31, 2020 — Blood vessel damage and inflammation in the brains of deceased COVID-19 patients suggest the damage is not caused by the virus, but the body’s immune response to it. The spots were surrounded by T cells — signs of an immune response. © 2020 HealthDay. Posted: December 2020.

Immune Response 52

Immune Response Virus Doctors Research 52

The Pharma Data

JANUARY 25, 2021

In a surprise move, Merck announced that it is giving up on its two coronavirus vaccine candidates after seeing a subpar immune response and shifting its focus to a pair of investigational coronavirus treatments. MK-7110, previously known as CD24Fc, is a recombinant fusion protein that controls the body’s inflammatory response.

Vaccine 52

Vaccine Immune Response Trials Clinical Trials 52

The Pharma Data

OCTOBER 21, 2020

22, 2020 (GLOBE NEWSWIRE) — Replimune Group, Inc. The offering is expected to close on October 26, 2020, subject to the satisfaction of customary closing conditions. headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immuno-gene therapies for the treatment of cancer. BOSTON, Oct.

Immune Response 40

Immune Response Clinical Trials Therapies Production 40

The Pharma Data

AUGUST 17, 2021

In the Opdivo plus Yervoy arm, patients received treatment with Opdivo 3 mg/kg every 2 weeks and Yervoy 1 mg/kg every 6 weeks up to 24 months or until disease progression or unacceptable toxicity. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.

Treatment 52

Treatment Immune Response Trials FDA Approval 52

The Pharma Data

DECEMBER 13, 2020

14, 2020 /PRNewswire/ — Synlogic, Inc. SYNB1891 is an investigational drug for the intra-tumoral treatment of solid tumors and lymphoma, composed of an engineered Synthetic Biotic designed to activate the STING pathway in the tumor microenvironment in order to upregulate the patient’s immune response.

Immune Response 40

Immune Response Treatment Engineering Clinical Trials 40

Drug Target Review

JANUARY 15, 2024

The pathogenesis of COPD is based on the innate and adaptive inflammatory immune response to the inhalation of toxic particles and gases. 1 Lung transplantation is the only viable treatment option, yet finding suitable lung donors is difficult. 2020 October 1 [2024 January 5]; 27(4):523-31. Cell Stem Cell.

Immune Response 113

Immune Response Disease Science Therapies 113

The Pharma Data

OCTOBER 27, 2020

27, 2020 /PRNewswire/ — Mirati Therapeutics, Inc. The offering is expected to close on or about October 30, 2020 , subject to customary closing conditions. SAN DIEGO , Oct. Nasdaq: MRTX) today announced the pricing of an underwritten public offering of 4,335,397 shares of its common stock at a price to the public of $202.00

Small Molecule 52

Small Molecule Immune Response Clinical Development Clinical Trials 52

Drug Target Review

OCTOBER 4, 2023

Antibody-drug conjugates (ADCs) have been a groundbreaking approach to cancer treatment with their ability to deliver cytotoxic drugs directly to diseased cells while sparing healthy tissues. 15 ISACs use small immuno-agonist molecules conjugated to the antibody to boost the immune response while minimising toxicity.

Small Molecule 126

Small Molecule Drugs Immune Response Targeted Protein Degradation 126

The Pharma Data

MAY 4, 2021

Tecentriq monotherapy has been shown to improve overall survival in people with high PD-L1 expression, when compared to chemotherapy, and therefore represents a new treatment option for people living with this difficult-to-treat disease.”. Grade 3–4 treatment-related adverse events were reported in 12.9% months (HR=0.76, 95% CI: 0.54–1.09).

Treatment 52

Treatment Therapies Disease Protein Expression 52

NIH Director's Blog: Drug Development

JUNE 30, 2020

But there is a catch: 99 percent of the study’s participants didn’t make enough neutralizing antibodies to mount an ideal immune response. That brings more reason for hope that the many vaccines now under study to elicit such neutralizing antibodies in sufficient numbers may afford us with much-needed immune protection.

Immune Response 52

Immune Response Virus Vaccine Research 52

The Pharma Data

MARCH 26, 2021

If approved, Tecentriq could offer people with a specific type of lung cancer a chemotherapy-free option in the first-line treatment setting. We remain committed to providing effective and tailored lung cancer treatment options, and this announcement is an important step toward this goal.”. months; hazard ratio [HR]=0.59, 95% CI: 0.40–0.89;

Treatment 52

Treatment Therapies Protein Expression Immune Response 52

Creative Biolabs

JULY 12, 2020

These antibodies can eliminate invaders and have great potential in the prevention and treatment of SARS-CoV-2 infection. ” The researchers studied the SARS-CoV-2 antibody response of 12 people who recovered from COVID-19. .” These neutralizing antibodies have been developed for the prevention and treatment of COVID-19.

Immune Response 52

Immune Response Laboratories Clinical Trials Clinical Development 52

The Pharma Data

JUNE 30, 2021

The EC’s decision is based on results from the Phase 2 CheckMate -142 trial in which Opdivo plus Yervoy demonstrated a clinically meaningful improvement in objective response rate (ORR) in patients with MSI-H/dMMR mCRC who received prior treatment with fluoropyridine, oxaliplatin and irinotecan. achieving a complete response.

Treatment 52

Treatment Trials FDA Approval Disease 52

The Pharma Data

DECEMBER 18, 2020

18, 2020 — Allergic reactions to vaccines are generally rare and people with common allergies are not more likely to have a reaction to the Pfizer-BioNTech COVID-19 vaccine, according to guidance released by the American College of Allergy, Asthma & Immunology (ACAAI). © 2020 HealthDay. Posted: December 2020.

Vaccine 52

Vaccine Immune Response Treatment Drugs 52

The Pharma Data

FEBRUARY 22, 2021

New Phase 2 study assesses potential for refined antigen formulation to achieve optimal immune response, including in older adults. Sanofi and GSK’s adjuvanted recombinant protein-based COVID-19 vaccine candidate was selected in July 2020 by the U.S. In parallel, development work on new SARS-CoV-2 variants underway.

Vaccine 52

Vaccine Immune Response Trials Clinical Trials 52

The Pharma Data

JUNE 26, 2021

We believe that mRNA technology could have several advantages for a seasonal flu application including the potential ability to demonstrate robust immune responses based on preclinical data to date, enable antigen specificity within a short timeframe from seasonal virus strain selection, and deploy agile manufacturing capacity.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

Drug Target Review

FEBRUARY 28, 2024

Over the past 25 years, T-cell therapies have gained significant ground in the treatment of cancer. Earlier in his career, Mr Ho was responsible for FP&A and operational analysis at CuraGen Corporation and worked as an Associate on the Healthcare Investment Banking team at Cowen, Inc. Cells 9(40):800 (2020).

Therapies 105

Therapies Engineering Molecular Biology Science 105

The Pharma Data

JUNE 25, 2021

CureVac began development of mRNA-based COVID-19 vaccine candidates in January 2020. Phase 1 and 2a clinical trials of CVnCoV began in June and September 2020, respectively. The quality of the immune response was comparable to recovered COVID-19 patients, closely mimicking the immune response after natural COVID-19 infection.

Vaccine 52

Vaccine Trials Immune Response Virus 52

The Pharma Data

SEPTEMBER 8, 2021

While these results are disappointing, w e believe th e rilzabrutinib clinical program holds great potential to address the unmet treatment needs of people living with immune-mediated diseases , ” said Naimish Patel, Head of Global Development, Immunology and Inflammation. “ 2020 Apr 9;72(9):1435–46. doi: 10.1002/art.41275.

Immune Response 52

Immune Response Trials Treatment Disease 52

The Pharma Data

DECEMBER 22, 2020

22, 2020 — In very rare cases, some people have had severe allergic reactions after receiving the new COVID-19 vaccines, leading the American College of Allergy , Asthma, and Immunology (ACAAI) to issue updated guidance for Americans with allergies. © 2020 HealthDay. Posted: December 2020. TUESDAY, Dec. Source link.

Vaccine 52

Vaccine Immune Response Treatment Disease 52

The Pharma Data

NOVEMBER 22, 2020

23, 2020 10:10 UTC. The TALON effector modules are based on immunomodulatory molecules that act as regulatory control points within the immune system. In conjunction with a tissue-specific targeting moiety, the effectors create novel bifunctional molecules for the treatment of autoimmune and inflammatory diseases.

Immune Response 52

Immune Response Engineering Clinical Research Disease 52

Drug Target Review

OCTOBER 26, 2023

1 Adeno-associated virus (AAV) vectors are the leading platform for in vivo gene delivery for the treatment of various human diseases. 9 In addition, host immune responses further add to the complexity of developing cell-specific AAV capsids for clinical applications. Nature 578 , 229-236 (2020). References Doudna JA.

Engineering 105

Engineering Virus Therapies Immune Response 105

The Pharma Data

NOVEMBER 9, 2020

10, 2020 06:00 UTC. Additionally, the vast majority of patients only receive a temporary benefit or no benefit from ICIs, as they either develop resistance to the treatment during the course of therapy or are non-responsive to the treatment altogether (only 15%-20% of patients respond, according to published data).

Immune Response 40

Immune Response Therapies Clinical Trials Treatment 40

The Pharma Data

OCTOBER 16, 2020

12 to 16, 2020. 16, 2020 — A case of reinfection with severe acute respiratory syndrome coronavirus 2 is described in a study published online Oct. COVID-19 Antibody Treatment Study Paused. Immune Responses Long-Lasting After Serious COVID-19. Reinfection With SARS-CoV-2 Described in 25-Year-Old. FRIDAY, Oct.

Hospitals 52

Hospitals Immune Response Trials Vaccine 52

The Pharma Data

NOVEMBER 12, 2020

12, 2020 — Lung cancer patients who harbor certain bacteria in the airways may have a poorer prognosis, a new study finds, adding to evidence that the body’s “microbiome” may play a role in cancer patients’ outlook. © 2020 HealthDay. Posted: November 2020. THURSDAY, Nov. All rights reserved.

Immune Response 52

Immune Response Research Doctors Treatment 52

The Pharma Data

NOVEMBER 12, 2020

12 November 2020 — The CALAVI Phase II trials for Calquence (acalabrutinib) in patients hospitalised with respiratory symptoms of COVID-19 did not meet the primary efficacy endpoint. Accessed October 2020. Accessed October 2020. Posted: November 2020. NCT identifier: NCT04380688. Available online.

Trials 52

Trials Clinical Trials Immune Response FDA Approval 52

NIH Director's Blog: Drug Development

MARCH 18, 2021

Now, Veesler and his lab are turning to another mammal in their search for new leads for the next generation of antiviral treatments, including ones aimed at the coronavirus that causes COVID-19, SARS-CoV-2. With support from a 2020 NIH Director’s Pioneer Award, Veesler will study members of the order Chiroptera.

Virus 52

Virus Immune Response Clinical Trials Treatment 52

Drug Target Review

MARCH 21, 2024

Could you elaborate on the safety profile observed in the study regarding the administration and treatment with Bobcat mRNA-DMD and how it compares to current therapeutic approaches for Duchenne muscular dystrophy? AAV-based therapies often can’t be dosed more than once due to concerns about an immune response. 2014 Jan 1;3.

Therapies 64

Therapies RNA Immune Response Treatment 64

The Pharma Data

OCTOBER 28, 2020

29, 2020 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on the potential pathway to marketing approval for its lead product candidate remestemcel-L. NEW YORK, Oct.

Treatment 40

Treatment Trials Production Disease 40

The Pharma Data

MARCH 11, 2021

Clinical trial to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels. The agreement was first expanded in March 2020 to include development of a novel mRNA vaccine for COVID-19. Expected to enroll 415 participants; interim results expected in Q3 2021.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

APRIL 22, 2023

The Atlas of MS reported in 2020 that someone is diagnosed with MS every five minutes around the world, adding to about 2.8 When infused back into a mouse model of MS, the backpack-laden monocytes were able to affect MS-specific immune responses, and partially reverse hind limb paralysis and improve motor functions.

Therapies 40

Therapies Immune Response Small Molecule Engineering 40

The Pharma Data

JUNE 26, 2021

BioNTech SE (NASDAQ: BNTX, “BioNTech” or “the Company”), announced that the first patient has been treated in its BNT111 Phase 2 cancer vaccine trial (2020-002195-12; NCT04526899). These results were published in Nature in July 2020. Co-founder and Chief Medical Officer of BioNTech. About BioNTech.

Clinical Trials 52

Clinical Trials Trials Immune Response Vaccine 52

The Pharma Data

JANUARY 3, 2021

Anecdotal feedback from Foralumab-treated patients was positive and suggests that the treatment was well-tolerated. This trial is the first to evaluate nasally administered Foralumab to improve the immune system’s fight against coronaviruses. NEW YORK and LONDON, Jan.

Clinical Trials 40

Clinical Trials Science Treatment Trials 40

The Pharma Data

DECEMBER 28, 2020

29, 2020 /PRNewswire/ — Moleculin Biotech , Inc., 29, 2020 /PRNewswire/ — Moleculin Biotech , Inc., Taken together, these factors suggest that Annamycin could represent an important treatment to help address a significant unmet need in patients with STS lung metastases. . .

FDA 52

FDA Clinical Trials Drugs Pharmaceutical Companies 52

The Pharma Data

DECEMBER 23, 2020

24, 2020 07:00 UTC. TREM-1 is an immunomodulatory receptor expressed on innate immune and endothelial cells which amplifies and maintains inflammation. Based upon an interim analysis, an independent DMC recommended on December 21, 2020 the continuation of Inotrem’s Phase IIa clinical trial for which results are expected early Q2 2021.

Clinical Trials 52

Clinical Trials Trials Research Immune Response 52

The Pharma Data

NOVEMBER 9, 2020

10, 2020 (GLOBE NEWSWIRE) — Immunophotonics, Inc. Coordinating Investigator of the trial commented, “IP-001 combines the promise of modern immunotherapy with the trend towards intratumoral treatment. SAKK is excited to bring this novel treatment to patients in desperate need for new innovative treatment options.”.

Clinical Trials 40

Clinical Trials Immune Response Trials Clinical Development 40

The Pharma Data

DECEMBER 22, 2020

22, 2020 — For Americans who are worried about the new coronavirus variant that is circulating in Britain, experts in the United States urge everyone to stay calm. ” How common are variants of viruses and do they generally impact effectiveness of vaccines or treatments? ” © 2020 HealthDay. TUESDAY, Dec.

Virus 52

Virus Vaccine Immune Response Treatment 52